News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
SAN DIEGO , Dec. 16, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
SAN DIEGO , Dec. 16, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Toggle Summary Adamis Pharmaceuticals Strengthens Patent Portfolio for its Dry Powder Inhaler
SAN DIEGO , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
Adamis Pharmaceuticals Strengthens Patent Portfolio for its Dry Powder Inhaler
SAN DIEGO , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
Toggle Summary Adamis Pharmaceuticals Announces $11.1 Million Registered Direct Offering
SAN DIEGO , July 29, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, and immunology, announced today that it has entered
Adamis Pharmaceuticals Announces $11.1 Million Registered Direct Offering
SAN DIEGO , July 29, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, and immunology, announced today that it has entered
Toggle Summary Adamis Pharmaceuticals Provides Update On License Agreement with Allergan plc 
SAN DIEGO , July 21, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has received notice from Allergan plc’s wholly owned subsidiary, Watson Laboratories, Inc. (“Watson”), that Watson has decided to terminate the previously
Adamis Pharmaceuticals Provides Update On License Agreement with Allergan plc 
SAN DIEGO , July 21, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has received notice from Allergan plc’s wholly owned subsidiary, Watson Laboratories, Inc. (“Watson”), that Watson has decided to terminate the previously
Toggle Summary Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO , July 12, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,724,137 shares of Series A-2 Convertible Preferred Stock to a small
Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO , July 12, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,724,137 shares of Series A-2 Convertible Preferred Stock to a small
Toggle Summary Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO , June 06, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company”) announced that after the close of the stock markets on June 3, 2016 it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) regarding its New Drug
Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO , June 06, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company”) announced that after the close of the stock markets on June 3, 2016 it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) regarding its New Drug
Toggle Summary Adamis Pharmaceuticals Announces License Agreement with Allergan plc Subsidiary for Epinephrine Pre-Filled Syringe
DUBLIN, Ireland and SAN DIEGO , May 10, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) has entered into an exclusive licensing agreement with Allergan plc’s wholly owned subsidiary, Watson Laboratories, Inc.
Adamis Pharmaceuticals Announces License Agreement with Allergan plc Subsidiary for Epinephrine Pre-Filled Syringe
DUBLIN, Ireland and SAN DIEGO , May 10, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) has entered into an exclusive licensing agreement with Allergan plc’s wholly owned subsidiary, Watson Laboratories, Inc.
Toggle Summary Adamis Pharmaceuticals Completes Acquisition of US Compounding
SAN DIEGO , April 12, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has successfully completed its previously announced acquisition (the “Acquisition”) of US Compounding, Inc.
Adamis Pharmaceuticals Completes Acquisition of US Compounding
SAN DIEGO , April 12, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has successfully completed its previously announced acquisition (the “Acquisition”) of US Compounding, Inc.
Toggle Summary Adamis Pharmaceuticals Announces Agreement to Acquire US Compounding
SAN DIEGO , March 29, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has entered into a definitive merger agreement (the “Agreement”) to acquire US Compounding, Inc.
Adamis Pharmaceuticals Announces Agreement to Acquire US Compounding
SAN DIEGO , March 29, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has entered into a definitive merger agreement (the “Agreement”) to acquire US Compounding, Inc.
Toggle Summary Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO , Jan. 26, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,183,432 shares of Series A-1 Convertible Preferred Stock to a
Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO , Jan. 26, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,183,432 shares of Series A-1 Convertible Preferred Stock to a
Toggle Summary Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO , Jan. 14, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO , Jan. 14, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Toggle Summary Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
SAN DIEGO , Dec. 07, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
SAN DIEGO , Dec. 07, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Toggle Summary Adamis Pharmaceuticals Provides Regulatory Update on Its Epinephrine Pre-Filled Syringe
SAN DIEGO , Aug. 06, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today provided an update on the status of and guidance for the resubmission of the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”) product
Adamis Pharmaceuticals Provides Regulatory Update on Its Epinephrine Pre-Filled Syringe
SAN DIEGO , Aug. 06, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today provided an update on the status of and guidance for the resubmission of the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”) product
Toggle Summary Adamis Pharmaceuticals Announces Key Additions to Its Commercial Sales Team
SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its commercial sales team. These appointments reflect the company's continuing preparations for a sales launch of its epinephrine pre-filled syringe (PFS) for
Adamis Pharmaceuticals Announces Key Additions to Its Commercial Sales Team
SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its commercial sales team. These appointments reflect the company's continuing preparations for a sales launch of its epinephrine pre-filled syringe (PFS) for
Toggle Summary Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO, March 27, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP
Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO, March 27, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP
Toggle Summary Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results For Its Dry Powder Inhaler Product
SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. The study was a Phase I PK study comparing the bioavailability of Adamis'
Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results For Its Dry Powder Inhaler Product
SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. The study was a Phase I PK study comparing the bioavailability of Adamis'
Toggle Summary Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results for Its Beclomethasone Dipropionate HFA Product
SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The study was a Phase I open label, randomized, single-dose,
Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results for Its Beclomethasone Dipropionate HFA Product
SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The study was a Phase I open label, randomized, single-dose,
Toggle Summary Adamis Pharmaceuticals Receives Notice of Allowance for US and Japanese Patents for Its Dry Powder Inhaler
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
Adamis Pharmaceuticals Receives Notice of Allowance for US and Japanese Patents for Its Dry Powder Inhaler
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Jan 09, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Jan 09, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan 08, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan 08, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Toggle Summary Adamis Pharmaceuticals To Present at Two Upcoming Conferences
SAN DIEGO, Dec 02, 2014 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  today announced that the Company is scheduled to present a company overview at two upcoming conferences. Event: 7th Annual LD Micro Conference Date: Wednesday, December 3, 2014
Adamis Pharmaceuticals To Present at Two Upcoming Conferences
SAN DIEGO, Dec 02, 2014 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  today announced that the Company is scheduled to present a company overview at two upcoming conferences. Event: 7th Annual LD Micro Conference Date: Wednesday, December 3, 2014
Toggle Summary Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
SAN DIEGO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a
Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
SAN DIEGO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a
Toggle Summary Adamis Pharmaceuticals Announces Appointment of New Members to its Board of Directors
SAN DIEGO, CA--(Marketwired - Aug 26, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Dr. Dennis J.
Adamis Pharmaceuticals Announces Appointment of New Members to its Board of Directors
SAN DIEGO, CA--(Marketwired - Aug 26, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Dr. Dennis J.
Toggle Summary Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Aug 19, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare
Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Aug 19, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare